Cryopreserved Platelets (CPP) for US FDA Licensure

SOL #: HT9427-26-RFI-705Sources Sought

Overview

Buyer

DEPT OF DEFENSE
Defense Health Agency (Dha)
ARMY MED RES ACQ ACTIVITY
FORT DETRICK, MD, 21702, United States

Place of Performance

Frederick, MD

NAICS

Research and Development in the Physical (541715)

PSC

No PSC code specified

Set Aside

No set aside specified

Timeline

1
Posted
Apr 23, 2026
2
Response Deadline
May 4, 2026, 7:00 PM

Qualification Details

Fit reasons
  • NAICS alignment with historical contract wins in similar service areas.
  • Scope strongly matches core technical capabilities and delivery model.
Risks
  • Past performance thresholds may require one additional teaming partner.
  • Potential clarification needed on staffing minimums before bid/no-bid.
Next steps

Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.

Quick Summary

The Defense Health Agency (DHA) is conducting a Sources Sought to identify capabilities for the development and US FDA licensure of Cryopreserved Platelets (CPP). This initiative aims to enhance Warfighter readiness by providing a platelet product with an extended shelf life. Responses are due May 4, 2026.

Scope of Work

The DHA seeks to develop and manage medical materiel, specifically focusing on Dimethyl Sulfoxide (DMSO) Cryopreserved Platelets (CPP). This biologic product is designed to offer a significantly longer shelf life (2 years and potentially more) compared to currently licensed liquid stored platelets (5-7 days). The goal is to improve the quality of life for active-duty personnel in operational environments.

Contract & Timeline

  • Type: Sources Sought / Request for Information (RFI)
  • Set-Aside: None specified
  • Response Due: May 4, 2026, 7:00 PM ET
  • Published: April 23, 2026
  • Place of Performance: Frederick, MD, United States

Evaluation

Responses will be utilized for market research and planning purposes to inform future acquisition strategies related to the FDA licensure of DMSO CPP.

Additional Notes

This notice is for informational purposes only and does not constitute a solicitation or commitment by the Government. Interested parties should review the attached document, "REQUEST FOR INFORMATION -HT9427-26-RFI-705.docx", for full details. Primary contact is Peter Mitchell (peter.d.mitchell8.civ@health.mil) and secondary contact is Kelly Green (kelly.r.green.civ@health.mil).

People

Points of Contact

Kelly GreenSECONDARY

Files

Files

Download

Versions

Version 1Viewing
Sources Sought
Posted: Apr 23, 2026
Cryopreserved Platelets (CPP) for US FDA Licensure | GovScope